– ISRAEL, Migdal HaEmek – Enzymotec Ltd. (Nasdaq:ENZY) a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today the appointment of Tamar Howson to its Board of Directors, effective July 29, 2015.
Steve Dubin, Enzymotec’s Chairman, commented, “I am delighted to have Ms. Howson join our Board of Directors. Ms. Howson brings with her a wealth of business development experience from the biotechnology and pharmaceutical industries, which will be an asset to our Board as well as to the entire company. I believe that Ms. Howson’s industry expertise will complement the company’s strategic growth initiatives. We look forward to her guidance and support as we further develop and execute on those initiatives.”
Tamar Howson added, “I am excited to have the opportunity to join Enzymotec’s Board of Directors and work with a team dedicated to leveraging its technology as it continues to focus on innovation. I look forward to applying my knowledge of the biotechnology and pharmaceutical industries to help drive their business development opportunities and growth initiatives.”
Tamar Howson, age 66, has served as a corporate business development and strategy consultant to biopharmaceutical companies since 2011. From 2009 to 2011, she worked for JSB-Partners, a transaction advisory firm, providing business development support to life sciences companies. From 2007 to 2008, Ms. Howson served as Executive Vice President, Corporate Business Development at Lexicon Pharmaceuticals. Ms. Howson also held the position of Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb from 2001 to 2007. Ms. Howson currently serves on the Board of Directors of publicly traded Organovo, Inc., OXiGENE, Inc. and Cynapsus, Inc. In the past, Ms. Howson served as a director of Actavis plc, Idenix Pharmaceuticals Inc., Warner Chilcott plc, Soligenix, Inc. and Cardax, Inc., all of which are publicly traded. In addition, Ms. Howson serves as a director of the International Partnership for Microbicides, a non-profit product development partnership. She has also served on the boards of Aradigm, S*BIO, Ariad Pharmaceuticals, SkyePharma, NPS Pharma, Targacept and HBA. Ms. Howson holds a bachelor’s degree in Chemical Engineering from the Technion, Israel, a MS from the City University of New York and an MBA from Columbia University.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.